Medical News

RSS

Reid's fight to get 60 votes dims Liberals' hopes of compromises in conference committee

Although the liberals and union leaders once hoped that a House-Senate conference committee could undo some of the compromises and move the health overhaul bill more to their liking, the "titanic struggle to lock in Sen. Ben Nelson (D-Neb.) as the 60th senator for the first key test vote early Monday morning has changed all that," Politico reports.

21 Dec 2009

ValueOptions employs TriZetto’s Clinical CareAdvance application

The TriZetto Group, Inc. today announced that ValueOptions® Inc., the nation’s largest independent behavioral healthcare and wellness company, recently went live with TriZetto’s Clinical CareAdvance® application 4.41 and expects to launch TriZetto’s Personal CareAdvance® application in early 2010.

21 Dec 2009

Democrats seek to regulate how insurers spend their customers' money

Kaiser Health News staff writer Julie Appleby explores the following concept advanced in current health overhaul plans. "Both the House measure and the newly recast Senate bill would force insurers to spend the vast majority of premium revenue on medical care for their customers, reducing the amount available for profits, executive salaries, sales and administration.

21 Dec 2009

Today's opinions and editorials

We usually associate presidential leadership with the pursuit of goals that, though initially unpopular, serve America's long-term interests. Obama has reversed this (Robert Samuelson, 12/21).

21 Dec 2009

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

Response Biomedical Corporation announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a continuation of the patent entitled “Sensitive Immunochromatographic Assay”. This patent covers key aspects of Response Biomedical’s lateral flow immunoassays with the proprietary RAMP® testing platform.

21 Dec 2009

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Idera Pharmaceuticals, Inc. today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.

21 Dec 2009

TessArae's RM-Flu test granted FDA EUA

TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.

21 Dec 2009

Cermetek Microelectronics launches UL 60601-1 compliant modem module

Cermetek Microelectronics, Inc. today announced the CH24606 modem module. The CH24606, a V.22bis modem module (2400 bits per second), is the first Cermetek modem designed to comply with UL 60601-1 requirements for medical equipment safety. Cermetek has targeted the CH24606 as a low-cost communications solution for medical monitoring equipment. The CH24606 sells for less than $15 in 1000 piece quantities.

21 Dec 2009

Walgreens discloses record first-quarter fiscal 2010 results

Walgreens today announced record earnings and sales for the first quarter of fiscal year 2010.

21 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.

21 Dec 2009

Believe only half of what men say

We hear a new story in the media every month: Celebrities, politicians, and high-profile businessmen cheating on their spouses. With these stories being so common, it's easy for single women to doubt that they could ever have a "happily ever after" ending in their own lives.

21 Dec 2009

CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial

CPEX Pharmaceuticals, Inc. today announced that the ongoing Phase 2a clinical trial of Nasulin™, the Company’s intranasal insulin candidate, has now completed enrollment. The study was initiated in February of this year and randomized 94 subjects. Results are expected at the end of the first quarter or beginning of the second quarter of 2010.

21 Dec 2009

FDA clears Dilon Diagnostics' GammaLoc lesion-localization system

Dilon Diagnostics announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its lesion-localization system for molecular imaging biopsy guidance.

21 Dec 2009

Investigation of IDH1 gene mutations in brain cancer receives new funds

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2’s funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios’s ongoing research into the development of new IDH1 therapeutics and diagnostics.

21 Dec 2009

Organogenesis files a PMA with the FDA for its CelTx living cell-based technology

Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.

21 Dec 2009

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.

21 Dec 2009

Durata Therapeutics acquires Vicuron Pharmaceuticals

Durata Therapeutics, Inc. announced today that it has acquired Vicuron Pharmaceuticals from Pfizer (PFE). Durata is a newly formed biopharmaceutical company that was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners.

21 Dec 2009

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

Sanofi-aventis to acquire Chattem for $1.9 billion

Sanofi-aventis and Chattem, Inc. announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire 100 percent of the outstanding shares of Chattem in a cash tender offer for $93.50 per share, or approximately $1.9 billion.

21 Dec 2009

Medical News

Reid's fight to get 60 votes dims Liberals' hopes of compromises in conference committee

ValueOptions employs TriZetto’s Clinical CareAdvance application

Democrats seek to regulate how insurers spend their customers' money

Today's opinions and editorials

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

TessArae's RM-Flu test granted FDA EUA

Cermetek Microelectronics launches UL 60601-1 compliant modem module

Walgreens discloses record first-quarter fiscal 2010 results

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Believe only half of what men say

CPEX Pharmaceuticals completes enrollment in Nasulin Phase 2a clinical trial

FDA clears Dilon Diagnostics' GammaLoc lesion-localization system

Investigation of IDH1 gene mutations in brain cancer receives new funds

Organogenesis files a PMA with the FDA for its CelTx living cell-based technology

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Durata Therapeutics acquires Vicuron Pharmaceuticals

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Sanofi-aventis to acquire Chattem for $1.9 billion

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Latest News